MedTrace Logo

PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children

NCT01734512 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 65

Last updated 2025-09-09

Study results available
· View outcomes & findings →

Summary

This is an open label study of everolimus in children with recurrent or progressive low-grade glioma.

Conditions

  • Pediatric Recurrent Progressive Low-grade Gliomas
  • Pediatric Progressive Low-grade Gliomas

Interventions

DRUG

Everolimus

Everolimus tablet will be taken daily by mouth with water. All participants will be given a dose of 5 mg/m2/dose daily.

Sponsors & Collaborators

Principal Investigators

  • Daphne Haas-Kogan, MD · Dana-Farber Cancer Institute

  • Sabine Mueller, MD · University of California, San Francisco

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
3 Years
Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-12-13
Primary Completion
2020-01-31
Completion
2024-07-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01734512 on ClinicalTrials.gov